Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Oridonin and docetaxel toxicity reducing and efficacy enhancing antitumor drug composition and application thereof

An anti-tumor drug, Rubescensine A technology, applied in the field of medical applications, can solve problems such as increasing anti-cancer effects, and achieve the effects of excellent inhibitory activity, reduced damage, and improved inhibitory activity

Active Publication Date: 2014-11-19
SHENZHEN UNIV
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] However, in the prior art, it is difficult to predict which combination of drugs can both increase the efficacy and attenuate the toxicity among the numerous anticancer drugs. In order to increase the anticancer effect and reduce its own toxicity, further in-depth research is needed in this field.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Oridonin and docetaxel toxicity reducing and efficacy enhancing antitumor drug composition and application thereof
  • Oridonin and docetaxel toxicity reducing and efficacy enhancing antitumor drug composition and application thereof
  • Oridonin and docetaxel toxicity reducing and efficacy enhancing antitumor drug composition and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0029] Example: Attenuation and enhancement experiments for various tumor cells and normal human cells

[0030] 1 Materials and methods

[0031] Instruments: (1) American Biotech Epoch microplate spectrophotometer; (2) American Thermo electric carbon dioxide incubator; (3) Singapore ESCO ultra-clean bench; (4) German Memmert water bath.

[0032] Cell lines: 7721 (human liver cancer cells), CFPAC-1 (human pancreatic cancer cells), DU145 (human prostate cancer cells), H441 (human lung cancer cells), HCT116 (human colon cancer cells), Hela (human cervical cancer cells) , MCF-7 (human breast cancer cells), 7701 (normal human liver cells)

[0033] Dosing concentration: Rubescensin A (25 μmol / L) + docetaxel concentration (25 μmol / L) ①, oridonin A concentration ① (50 μmol / L), docetaxel concentration ① (50 μmol / L), Rubescensin A (12.5 μmol / L) + docetaxel concentration (12.5 μmol / L) ②, oridonin A concentration (25 μmol / L) ②, docetaxel concentration (25 μmol / L) ②

[0034] Method: Spr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an oridonin and docetaxel toxicity reducing and efficacy enhancing antitumor drug composition and application thereof. Active ingredients playing the roles of toxicity reduction and efficacy enhancement are oridonin and docetaxel. The medicine composition has an obvious synergistic interaction effect on various tumor cells, obviously has smaller toxicity on various normal cells of a human body in comparison with single use of a medicine, reduces harm on the body, and plays the roles of reducing toxicity and enhancing efficacy. Owing to the specific toxicity reducing and efficacy enhancing effects, the medicine composition can be widely used for treating cancers of human bodies.

Description

technical field [0001] The invention belongs to the field of medical applications, in particular to an attenuated and synergistic antitumor pharmaceutical composition composed of oridonin A and docetaxel and its application. Background technique [0002] Cancer is one of the leading causes of death in humans, and it is extremely difficult to treat. The incidence of cancer has been on the rise for nearly 30 years in the late 20th century. According to the report of the World Health Organization (WH Rubescensin A), the number of new cancer cases in the world in 1990 was about 8.07 million, an increase of 37.4% compared with 5.17 million in 1975. %, in 1997, the number of cancer deaths in the world was about 6.2 million. According to the current trend, with the world population reaching 8 billion by 2020, there will be 20 million new cancer cases, of which the death toll will reach 12 million, and most of them will be occur in developing countries. [0003] Since 1970, the nu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61P35/00A61K31/337
Inventor 张波贺震旦
Owner SHENZHEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com